ReviewFrontiers in neurology2025
Systemic inflammation-based hematological indices and 90-day functional outcomes after intravenous thrombolysis in acute ischemic stroke: a systematic review.
Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Intravenous Thrombolysis Preceding Mechanical Thrombectomy in Patients with Acute Ischemic Stroke Reduces the Inflammatory Response: Preliminary Results Based on Retrospective Analysis of Medical Documentation.Journal of clinical medicine · 2026Article
- Immunotherapies for Ischemic Stroke Patients: Current Status and Future Directions.Medical sciences (Basel, Switzerland) · 2026Review
- Study on the Association Between the Systemic Immune-Inflammation Index and Polycystic Ovary Syndrome in Women Undergoing in vitro Fertilization for Subfertility.International journal of women's health · 2026Article
- Preoperative differentiation of acute appendicitis using NLR, SII, and maximum appendiceal diameter: a retrospective single-center diagnostic study.Frontiers in surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute ischemic stroke (AIS) is one of the leading causes of mortality and long-term disability worldwide. Intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator (rt-PA) remains the standard treatment for eligible patients; however, considerable inter-individual variability exists in post-treatment functional outcomes. Increasing evidence suggests that systemic inflammation plays a crucial regulatory role in both ischemic injury cascades and reperfusion efficacy. In recent years, several inflammation-based hematological indices derived from complete blood counts-such as the neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), inflammation prognostic index (IPI), and pan-immune-inflammation value (PIV)-have been proposed. These indices comprehensively reflect the balance between innate immune activation and adaptive immune suppression and are considered potential prognostic biomarkers. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we systematically searched PubMed, Embase, and Web of Science for English-language studies published between 2015 and 2025 investigating the relationship between inflammation-based hematological indices and functional outcomes in adult AIS patients receiving intravenous rt-PA. Eligible studies were limited to IVT-only cohorts reporting associations between composite inflammatory indices and clinical outcomes. The search strategy was framed using the PICO (Population, Intervention, Comparison, and Outcome) approach, and study quality was assessed using the Newcastle-Ottawa Scale (NOS). Results: A total of 15 observational cohort studies involving approximately 4,000 AIS patients were included. Higher baseline or early values of NLR, SII, SIRI, and PIV were independently associated with unfavorable 90-day functional outcomes, with predictive performance (AUC) generally ranging from 0.70 to 0.80. Several studies further indicated that dynamic changes in inflammatory indices within 24-48 h after IVT provided stronger prognostic discrimination than baseline measurements, underscoring the clinical value of early immune monitoring during the acute phase of stroke. Conclusion: Systemic inflammation plays a central role in the pathophysiology and therapeutic response of AIS. Composite inflammation-based hematological indices are simple, economical, and reproducible tools that may assist in early risk stratification and individualized prognostic assessment following IVT. Future studies should incorporate dynamic longitudinal monitoring and integrate multimodal clinical and biomarker data within large, multicenter cohorts to improve model precision and enhance translational applicability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.